QiLin-assistedphysician only, without QiLin assisted
QiLin-assisted: A Comprehensive Deep Learning Model for Assisting the decision of anti-VEGF therapy: QiLin system
physician only, without QiLin assisted: without QiLin assisted
Study summary
We developed an artificial intelligence system, called QiLin, which was designed to assist anti-VEGF treatment decisions in retinal diseases. QiLin was trained and validated via over 20,000 optical coherence tomography images from multicenter datasets, demonstrating strong performance on both internal and external validation. To evaluate its real-world clinical utility, we conducted a randomized controlled trial that rigorously compares the accuracy of treatment decisions between a physician-only arm and an AI-assisted physician arm.
Eligibility
Sex
ALL
Min age
50 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria:
Patients with a diagnosis of nAMD, DME, and RVO; Patients who have completed the loading-dose treatment of anti-VEGF agents; Patients who were willing to participate and provided written informed consent.
Exclusion Criteria:
Refusal to undergo OCT testing; Refusal to complete the 3-month follow-up period; Screening for a history of intraocular surgery within the past 6 months; Subjects with severe systemic diseases, intellectual developmental disorders, psychiatric illnesses, etc.
Primary outcome measure(s)
Accuracy of the current anti-VEGF injection decision — At enrollment The accuracy of the current anti-VEGF injection decision was defined as the proportion of injection decisions (yes or no) made by the physicians in the two arms that were in agreement with the independent senior expert.
Trial sites (2)
Facility
City
Region
Status
Shanghai general hospital, Shanghai Jiao Tong University, Shanghai, 200080
Shanghai
China
Shanghai general hospital
Shanghai
China
More Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.